Patents by Inventor Anwer Basha

Anwer Basha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS
    Publication number: 20120208820
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Application
    Filed: January 31, 2012
    Publication date: August 16, 2012
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
  • Diazabicyclic central nervous system active agents
    Patent number: 8119635
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: February 21, 2012
    Assignee: Abbott Laboratories
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
  • DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS
    Publication number: 20100016277
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Application
    Filed: August 19, 2009
    Publication date: January 21, 2010
    Applicant: ABBOTT LABORATORIES
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
  • Diazabicyclic central nervous system active agents
    Patent number: 7598236
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Grant
    Filed: December 15, 2007
    Date of Patent: October 6, 2009
    Assignee: Abbott Laboratories
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Frost, Kevin B. Sippy
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20090042888
    Abstract: The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
    Type: Application
    Filed: June 23, 2006
    Publication date: February 12, 2009
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS
    Publication number: 20080097094
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Application
    Filed: December 15, 2007
    Publication date: April 24, 2008
    Applicant: Abbott Laboratories
    Inventors: Michael Schrimpf, Karin Tietje, Richard Toupence, Jianguo Ji, Anwer Basha, William Bunnelle, Jerome Daanen, Jennifer Frost, Kevin Sippy
  • Diazabicyclic central nervous system active agents
    Patent number: 7319106
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: January 15, 2008
    Assignee: Abbott Laboratories
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Pace, Kevin B. Sippy
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Patent number: 7115591
    Abstract: The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently markered non-steroidal anti-inflammatory drugs (NSAIDs).
    Type: Grant
    Filed: June 19, 2003
    Date of Patent: October 3, 2006
    Assignee: Abbott Laboratories
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Patent number: 7001895
    Abstract: The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
    Type: Grant
    Filed: April 17, 2003
    Date of Patent: February 21, 2006
    Assignee: Abbott Laboratories
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Substituted diazabicycloalkane derivatives
    Publication number: 20050101602
    Abstract: Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
    Type: Application
    Filed: September 16, 2004
    Publication date: May 12, 2005
    Inventors: Anwer Basha, William Bunnelle, Michael Dart, Megan Gallagher, Jianguo Ji, Tao Li, Jennifer Pace, Keith Ryther, Karin Tietje, Kathleen Mortell, Diana Nersesian, Michael Schrimpf
  • Substituted diazabicycloakane derivatives
    Publication number: 20050065178
    Abstract: Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by ?7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.
    Type: Application
    Filed: September 19, 2003
    Publication date: March 24, 2005
    Inventors: Anwer Basha, William Bunnelle, Michael Dart, Megan Gallagher, Jianguo Ji, Tao Li, Jennifer Pace, Keith Ryther, Karin Tietje
  • Diazabicyclic central nervous system active agents
    Patent number: 6809105
    Abstract: Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: October 26, 2004
    Assignee: Abbott Laboratories
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Pace, Kevin B. Sippy
  • Diazabicyclic central nervous system active agents
    Publication number: 20040186107
    Abstract: Compounds of formula I 1
    Type: Application
    Filed: March 26, 2004
    Publication date: September 23, 2004
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Pace, Kevin B. Sippy
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20040158064
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: June 19, 2003
    Publication date: August 12, 2004
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20030225276
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: April 17, 2003
    Publication date: December 4, 2003
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission
    Publication number: 20020151712
    Abstract: A series of 3-pyrrolidinyloxy-3′-pyridyl ether compounds, a method for selectively controlling neurotransmitter release in mammals using these compounds, and pharmaceutical compositions including these compounds. Preferred compounds are 3-pyrrolidinylmethoxy-3′-(5′-and/or 6′-substituted) pyridyl ethers.
    Type: Application
    Filed: March 19, 2002
    Publication date: October 17, 2002
    Inventors: Nan-Horng Lin, Yihong Li, Irene Drizin, John F. Kincaid, Anwer Basha, Liming Dong, Ahmed A. Hakeem
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20020028938
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: May 31, 2001
    Publication date: March 7, 2002
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Diazabicyclic central nervous system active agents
    Publication number: 20020019388
    Abstract: Compounds of formula I 1
    Type: Application
    Filed: April 12, 2001
    Publication date: February 14, 2002
    Inventors: Michael R. Schrimpf, Karin R. Tietje, Richard B. Toupence, Jianguo Ji, Anwer Basha, William H. Bunnelle, Jerome F. Daanen, Jennifer M. Pace, Kevin B. Sippy
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20020013318
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: May 31, 2001
    Publication date: January 31, 2002
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • AZOLE INHIBITORS OF CYTOKINE PRODUCTION
    Publication number: 20010044445
    Abstract: Compounds having the formula 1
    Type: Application
    Filed: April 8, 1999
    Publication date: November 22, 2001
    Inventors: NWE Y. BAMAUNG, ANWER BASHA, STEVAN W. DJURIC, EARL J. GUBBINS, JAY R. LULY, NOAH P. TU, DAVID J. MADAR, USHA WARRIOR, PAUL E. WIEDEMAN, XUN ZHOU, RICHARD J. SCIOTTI, FRANK L. WAGENAAR